FATE THERAPEUTICS INC Paid-in-Kind Interest
FATE THERAPEUTICS INC (FATE) reported Paid-in-Kind Interest of $238.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2021-02-24
- FATE THERAPEUTICS INC paid-in-kind interest for the quarter ending 2019-09-30 was $79.00K, a 15.96% decline year-over-year.
- FATE THERAPEUTICS INC paid-in-kind interest for the quarter ending 2019-06-30 was $80.00K, a 13.98% decline year-over-year.
- FATE THERAPEUTICS INC paid-in-kind interest for the quarter ending 2019-03-31 was $79.00K, a 14.13% decline year-over-year.
- FATE THERAPEUTICS INC paid-in-kind interest for the quarter ending 2018-12-31 was $94.00K, a 0.00% change year-over-year.
- FATE THERAPEUTICS INC paid-in-kind interest for fiscal 2018 was $373.00K, a 16.20% increase from fiscal 2017.
- FATE THERAPEUTICS INC paid-in-kind interest for fiscal 2017 was $321.00K, a 34.76% decline from fiscal 2016.
- FATE THERAPEUTICS INC paid-in-kind interest for fiscal 2016 was $492.00K, a 24.42% decline from fiscal 2015.
- FATE THERAPEUTICS INC paid-in-kind interest for fiscal 2015 was $651.00K, a 289.82% increase from fiscal 2014.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month | Paid-in-Kind Interest 77 month | Paid-in-Kind Interest 80 month | Paid-in-Kind Interest 83 month |
|---|---|---|---|---|---|---|---|
| 2019-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $159.00K derived: sum of 2 quarters · filed 2020-11-05 | $238.00K 10-Q · filed 2020-11-05 | $332.00K derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $159.00K 10-Q · filed 2020-08-05 | $253.00K derived: sum of 3 quarters · filed 2021-02-24 | $347.00K derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-03-31 | $79.00K 10-Q · filed 2020-05-11 | $173.00K derived: sum of 2 quarters · filed 2021-02-24 | $267.00K derived: sum of 3 quarters · filed 2021-02-24 | $360.00K derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $188.00K derived: sum of 2 quarters · filed 2021-02-24 | $281.00K derived: sum of 3 quarters · filed 2021-02-24 | $373.00K 10-K · filed 2021-02-24 | |||
| 2018-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $187.00K derived: sum of 2 quarters · filed 2019-11-05 | $279.00K 10-Q · filed 2019-11-05 | $373.00K derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $185.00K 10-Q · filed 2019-08-06 | $279.00K derived: sum of 3 quarters · filed 2020-03-02 | $368.00K derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | $92.00K 10-Q · filed 2019-05-07 | $186.00K derived: sum of 2 quarters · filed 2020-03-02 | $275.00K derived: sum of 3 quarters · filed 2020-03-02 | $336.00K derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $183.00K derived: sum of 2 quarters · filed 2020-03-02 | $244.00K derived: sum of 3 quarters · filed 2020-03-02 | $321.00K 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $150.00K derived: sum of 2 quarters · filed 2018-11-01 | $227.00K 10-Q · filed 2018-11-01 | $323.00K derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $138.00K 10-Q · filed 2018-08-06 | $234.00K derived: sum of 3 quarters · filed 2019-03-05 | $346.00K derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2017-03-31 | $77.00K 10-Q · filed 2018-05-10 | $173.00K derived: sum of 2 quarters · filed 2019-03-05 | $285.00K derived: sum of 3 quarters · filed 2019-03-05 | $412.00K derived: sum of 4 quarters · filed 2019-03-05 | |||
| 2016-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $208.00K derived: sum of 2 quarters · filed 2019-03-05 | $335.00K derived: sum of 3 quarters · filed 2019-03-05 | $492.00K 10-K · filed 2019-03-05 | |||
| 2016-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $239.00K derived: sum of 2 quarters · filed 2017-11-01 | $396.00K 10-Q · filed 2017-11-01 | $553.00K derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $284.00K 10-Q · filed 2017-08-14 | $441.00K derived: sum of 3 quarters · filed 2018-03-05 | $606.00K derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-03-31 | $157.00K 10-Q · filed 2017-05-15 | $314.00K derived: sum of 2 quarters · filed 2018-03-05 | $479.00K derived: sum of 3 quarters · filed 2018-03-05 | $644.00K derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2015-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $322.00K derived: sum of 2 quarters · filed 2018-03-05 | $487.00K derived: sum of 3 quarters · filed 2018-03-05 | $651.00K 10-K · filed 2018-03-05 | |||
| 2015-09-30 | $165.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $330.00K derived: sum of 2 quarters · filed 2016-11-07 | $494.00K 10-Q · filed 2016-11-07 | $585.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $329.00K 10-Q · filed 2016-08-08 | $420.00K derived: sum of 3 quarters · filed 2017-03-16 | $479.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | $164.00K 10-Q · filed 2016-05-09 | $255.00K derived: sum of 2 quarters · filed 2017-03-16 | $314.00K derived: sum of 3 quarters · filed 2017-03-16 | $321.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $150.00K derived: sum of 2 quarters · filed 2017-03-16 | $157.00K derived: sum of 3 quarters · filed 2017-03-16 | $167.00K 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $66.00K derived: sum of 2 quarters · filed 2015-11-03 | $76.00K 10-Q · filed 2015-11-03 | $89.00K derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $17.00K 10-Q · filed 2015-08-05 | $30.00K derived: sum of 3 quarters · filed 2016-03-03 | $122.00K derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | $10.00K 10-Q · filed 2015-05-07 | $23.00K derived: sum of 2 quarters · filed 2016-03-03 | $115.00K derived: sum of 3 quarters · filed 2016-03-03 | $135.00K derived: sum of 4 quarters · filed 2016-03-03 | $1.18M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $105.00K derived: sum of 2 quarters · filed 2016-03-03 | $125.00K derived: sum of 3 quarters · filed 2016-03-03 | $147.00K 10-K · filed 2016-03-03 | $1.17M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $112.00K derived: sum of 2 quarters · filed 2014-11-12 | $134.00K 10-Q · filed 2014-11-12 | $158.00K derived: sum of 4 quarters · filed 2015-03-12 | $1.16M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $42.00K 10-Q · filed 2014-08-12 | $66.00K derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $22.00K 10-Q · filed 2014-05-13 | $46.00K derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $121.00K 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | $97.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | $13.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |